OPKO signs licensing deal for prostate cancer tests
The OPKO test panel will combine PSA and two novel kallikrein markers to provide greater accuracy. The biomarkers were developed by investigators at the University of Malmo, Sweden,
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).
NextDocs’solutions can ensure users the consistency of workflow processes and document handling, with the capability of re-engineering business processes using workflow controls if necessary. In addition, NextDocs’ collection